Synhealer

Synhealer LTD is at the forefront of next-generation immuno-oncology, pioneering CAR-macrophage (CAR-M) therapies specifically designed to target solid tumors. Our primary  focus is on liver cancer (HCC) patients who are resistant to current treatment such as immune checkpoint inhibitors. **Why Synhealer** •The world’s first EPSC-derived CAR-M therapy •First CAR-M Company headquartered in HK •Dual targeting approach via engineered antibody-secreting CAR-M combining antibody technology (AB) with CAR-M Our innovative CAR-M therapy enhances tumor targeting and immune activation, tackling solid tumours that evade conventional treatments.